Trial Profile

A randomised, placebo-controlled single and multiple ascending dose study to test the safety, tolerability, pharmacokinetics and pharmacodynamics of NT-0249 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NT-0249 (Primary)
Indications Inflammation
Focus First in man; Therapeutic Use
Sponsors Nodthera

Most Recent Events

21 Sep 2022 According to Nodthera media release, NT-0249 that has successfully completed its Phase 1 single ascending dose study.
21 Sep 2022 Interim results published in Nodthera Media Release.
10 May 2022 Status changed from not yet recruiting to recruiting, according to Nodthera media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com